# TiCARos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ticaros

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.ticaros.com
- Total disclosed funding: $43M
- Latest round: Series D (Mar 3, 2026)
- Investors on record: 15

## About

Based in Seoul, South Korea, and founded in 2018, TiCARos specializes in developing immuno-oncology treatment by leveraging CAR-T therapy. On its establishment in 2018, the company had a research partnership with the National Cancer Center. In 2020, Prof. Sung-soo Yoon of Seoul National University Hospital was appointed as a scientific advisor and the company made a research partnership with Seoul National University Hospital, Division of Hematology & Medical Oncology. In March 2026, TiCARos raised KRW 20.8 billion in series D funding from Kiwoom Securities, iM Investment Partners, and SJ Investment Partners.

The company develops the CAR-T manufacturing process by introducing Miltenyi's CliniMACS Prodigy equipment, a closed and fully automated system from the initial development stage. This established a system that can produce reproducible and safe CAR-T therapeutics by minimizing process variables compared to manual production by researchers and preventing cross-contamination through closed system production. The company plans to allocate the March 2026 funds towards the completion of clinical trials for its blood cancer medication and the initiation of trials for its tumor treatment.

## Funding rounds

- Series D, Mar 3, 2026, $15M — Kiwoom Securities, SJ Investment Partners, iM Investment Partners
- Series C, Aug 24, 2021, $21M — Shinhan Venture Investment, Daesung Private Equity, Posco Investment, UTC Investment, Medici Investment, Holistic Growth Initiative, Woori Investment Bank, Korea SMEs and Startups Agency, Kingo Investment Partners, Dimension Investment Management
- Series B, Jan 4, 2020, $5.2M — SJ Investment Partners, E&Venture Partners, Medytox Venture Investment
- Series A, Feb 28, 2019, $1.8M — SJ Investment Partners

## Investors

- SJ Investment Partners (https://capitalatlas.ai/funds/sj-investment-partners) — Series A, Series B, Series D
- E&Venture Partners (https://capitalatlas.ai/funds/e-venture-partners) — Series B
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Series B
- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series C
- Daesung Private Equity (https://capitalatlas.ai/funds/daesung-private-equity) — Series C
- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Series C
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series C
- Medici Investment (https://capitalatlas.ai/funds/medici-investment) — Series C
- Holistic Growth Initiative (https://capitalatlas.ai/funds/holistic-growth-initiative) — Series C
- Woori Investment Bank (https://capitalatlas.ai/funds/woori-investment-bank) — Series C
- Korea SMEs and Startups Agency — Series C
- Kingo Investment Partners (https://capitalatlas.ai/funds/kingo-investment-partners) — Series C
- Dimension Investment Management — Series C
- Kiwoom Securities — Series D
- iM Investment Partners (https://capitalatlas.ai/funds/im-investment-partners) — Series D